Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is conducted to evaluate the safety/tolerability and PK/PD of JW1601 after oral administration in healthy Korean, Caucasian and Japanese adult volunteers
This is a dose block-randomized, double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability and PK/PD profile by administering investigational product (IP) as a single dose (One time) or repeated doses (7 days, once a day) orally in a fasted state.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| JW1601 | Experimental | tablet formulation |
|
| Placebo | Placebo Comparator | tablet formulation identified with JW1601 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Study drug | Drug | oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety and tolerability after single ascending dose administration based on laboratory values, vital signs, ECG, physical examinations and Adverse Events monitoring | AE incidence and the value or the change from baseline such as vital signs, 12-lead ECG, and clinical laboratory tests will be compared by each group and placebo group. | From Day 1 through Post Study Visit (Day 8) |
| Safety and tolerability in multiple ascending dose administration based on laboratory values, vital signs, ECG, physical examinations and Adverse Events monitoring | AE incidence and the value or the change from baseline such as vital signs, 12-lead ECG, and clinical laboratory tests will be compared by each group and placebo group. | From Day 1 through Post Study Visit (Day 14) |
| Measure | Description | Time Frame |
|---|---|---|
| Cmax in plasma in single ascending dose administration | Maximum concentration of drug in plasma | Baseline(Day 1) through Day 4 |
| Tmax in plasma in single ascending dose administration | Time to maximum plasma concentration |
Not provided
Inclusion Criteria:
- Subjects who have voluntarily given written informed consent to participate in the study and comply with all study requirements after getting detailed explanation and full understanding of the study
Exclusion Criteria:
- Subjects judged by the investigators unsuitable for participating in the study based on any other reasons
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Minsoo Park, MD | Severance Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Severance Hospital | Seoul | 06725 | South Korea | |||
| Seoul National University Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004341 | Drug Evaluation |
| ID | Term |
|---|---|
| D000076722 | Drug Development |
| D008919 | Investigative Techniques |
| D005069 | Evaluation Studies as Topic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets |
|
| Baseline(Day 1) through Day 4 |
| AUClast in plasma in single ascending dose administration | Area under the plasma drug concentration-time curve to last measurement | Baseline(Day 1) through Day 4 |
| Eosinophil shape change(%) in single ascending dose administration | Imetit-induced eosinophil shape change | Baseline(Day -1) through Day 4 |
| QT/QTc changes in single ascending dose administration | 12-lead ECG | Baseline(Day -1), Day 1, Day 2 |
| C(max, ss) in plasma in multiple ascending dose administration | Maximum concentration of drug in plasma (at steady state) | Baseline(Day 1) through Day 10 |
| T(max,ss) in plasma in multiple ascending dose administration | Time to maximum plasma concentration (at steady state) | Baseline(Day 1) through Day 10 |
| AUC(τ,ss) in plasma in multiple ascending dose administration | Area under the plasma drug concentration-time curve within a dosing interval(τ) at steady state | Baseline(Day 1) through Day 10 |
| Eosinophil shape change(%) in multiple ascending dose administration | Imetit-induced eosinophil shape change | Baseline(Day -1) through Day 10 |
| QT/QTc changes in multiple ascending dose administration | 12-lead ECG | Baseline(Day -1), Day 7, Day 8 |
| Seoul |
| South Korea |